As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai ...
STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Recipharm AB today announces that it has entered into an agreement to acquire Italian CDMO, Mitim Srl adding scale and capabilities to the group. Mitim is ...
Recipharm and Exela Pharma Sciences entered into an exclusive strategic alliance aimed at enhancing their combined CDMO sterile manufacturing capabilities in the United States. This collaboration will ...
Another sign that the post-pandemic reshaping of the CDMO industry isn't over came Tuesday as one of the sector’s most powerful companies, Recipharm, sold off seven of its manufacturing and ...
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPF) today announced that it has commenced litigation against Recipharm Limited (“Recipharm”) ...
JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics and ...
JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and ...
TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today announced that it had accepted a Part 36 settlement offer made by ...
Renal insufficiency hydrocortisone drug was approved in Europe in November. ViroPharma contracted Recipharm to carry out full commercial-scale manufacture of Plenadren®, a modified release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results